| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 02/25/2004 | EP0751957B1 Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases |
| 02/25/2004 | CN1478098A Modulation of IL-2-and IL-15-mediated T cell responses |
| 02/25/2004 | CN1478089A Substituted derivatives of aminofuran-2-Y1-acetic acid and aminothien-2-Y1-acetic acid and use thereof for treating migraines and pain |
| 02/25/2004 | CN1478087A Indolylmaleimide derivatives as protein kinase C inibitors |
| 02/25/2004 | CN1478084A Compounds useful in treatment of inflammatory diseases |
| 02/25/2004 | CN1478078A Nitrogenous aromatic ring compounds |
| 02/25/2004 | CN1478067A O-substituted 6-methyl-tramadol derivatives |
| 02/25/2004 | CN1477968A Methods for treating rheumatic diseases using soluble CTLA4 molecule |
| 02/25/2004 | CN1477967A Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 02/25/2004 | CN1477963A Organic compounds |
| 02/25/2004 | CN1477960A EPA receptor inhibitors to treat rheumatoid arthritis |
| 02/25/2004 | CN1477955A Parenteral dosage forms comprising suspension of tramadol salt and diclofenac salt |
| 02/25/2004 | CN1476890A Chinese medicine composition for curing child common cold fever |
| 02/25/2004 | CN1476884A Inflammation-relieving plaster and its production method |
| 02/25/2004 | CN1476874A Fengshi Mamu liquor for curing rheumatic numbness |
| 02/25/2004 | CN1476862A Fengshitong capsule for curing rheumatalgia |
| 02/25/2004 | CN1476860A Xiaotongshu plaster and its preparation method |
| 02/25/2004 | CN1476856A Qianghua Poyutongluo powder preparation for curing osteodynia and its preparation method |
| 02/25/2004 | CN1476847A Chinese medicine oil preparation for promoting blood circulation |
| 02/25/2004 | CN1139595C Crystalline macrolides and its preparation method |
| 02/25/2004 | CN1139570C Inhibition of matrix metalloproteases by acetylene-containing compound |
| 02/25/2004 | CN1139397C Plaster for treating hyperosteogeny and osteoarthropathy and its producing method |
| 02/24/2004 | US6696567 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/24/2004 | US6696566 Selective p38 kinase inhibitors relative to cyclin-dependent kinases and tyrosine kinases |
| 02/24/2004 | US6696498 2-cyclopenten-1-one and its derivatives as inhibitors of the NF-kB factor |
| 02/24/2004 | US6696471 Aminopyrrole compounds |
| 02/24/2004 | US6696470 Pyridylthiophene compounds |
| 02/24/2004 | US6696464 Triazolo-pyridines anti-inflammatory compounds |
| 02/24/2004 | US6696458 Having x-ray powder diffraction pattern with lines at degrees 2 theta values 6.7, 12.5, 14.0 and 23.9 for cu k alpha radiation of wavelength 1.5406 angstrom |
| 02/24/2004 | US6696457 Morphinoid compounds |
| 02/24/2004 | US6696452 Glycogen synthase kinase-3 and aurora-2 a serine/threonine protein kinase inhibitors; antidiabetic and anticancer agents and alzheimer's disease treatments |
| 02/24/2004 | US6696449 Control degradation of conencting tissue; cardiovascular disorders |
| 02/24/2004 | US6696446 Benzoylpyridazines, their preparation and use |
| 02/24/2004 | US6696445 Neuropeptide y receptor antagonists comprising heterocyclic nitrogen compounds and/or prodrugs used for prophylaxis of eating and cardiovascular disorders |
| 02/24/2004 | US6696443 Piperidine/piperazine-type inhibitors of p38 kinase |
| 02/24/2004 | US6696437 Polymerase inhibitors comprising heterocyclic amides such as 2-pyridin-2-ylbenzimidazole-4-carboxamide, used for prophylaxis of neurodegenerative disorders, damage to hearts or brains, and as anticarcinogenic agents |
| 02/24/2004 | US6696434 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 02/24/2004 | US6696412 Purification of daptomycin by binding to ion exchange resins in the presence of buffers and chaotropic agents, then eluting and recovering; peptide antibiotics |
| 02/24/2004 | US6696408 Administering glycosylated polypeptides as antiepileptics and anticonvulsants or for prophylaxis of psychological disorders |
| 02/24/2004 | CA2293461C Alkyl-4-silylheterocyclic phenols and thiophenols as antioxidant agents |
| 02/24/2004 | CA2279186C Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| 02/24/2004 | CA2219081C Angiostatin fragments and aggregate angiostatin and methods of use |
| 02/24/2004 | CA2132213C Specific detection of cell surface receptor leukocyte adhesion molecule-1 |
| 02/23/2004 | CA2399630A1 Scyphostatin analogues as smase inhibitors |
| 02/19/2004 | WO2004015109A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use |
| 02/19/2004 | WO2004015100A1 Method of judging inflammatory disease |
| 02/19/2004 | WO2004014927A1 Mitochondrially targeted antioxidants |
| 02/19/2004 | WO2004014923A1 Pyrimidinone fused bicyclic metalloproteinase inhibitors |
| 02/19/2004 | WO2004014920A1 Bicyclic heteroaromatic compounds as kinase inhibitors |
| 02/19/2004 | WO2004014916A1 Pyrimidine fused bicyclic metalloproteinase inhibitors |
| 02/19/2004 | WO2004014913A2 Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014911A1 Phosphodiesterase 4 inhibitors |
| 02/19/2004 | WO2004014909A1 Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014908A1 Heterobicylcic metalloproteinase inhibitors |
| 02/19/2004 | WO2004014907A1 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
| 02/19/2004 | WO2004014905A1 Substituted benzimidazole compounds |
| 02/19/2004 | WO2004014903A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| 02/19/2004 | WO2004014892A1 Monocyclic derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014880A1 Chromone derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014878A1 1,2,4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same |
| 02/19/2004 | WO2004014873A1 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| 02/19/2004 | WO2004014871A1 Vanilloid receptor ligands and their use in treatments |
| 02/19/2004 | WO2004014869A2 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014868A2 Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014866A1 Azaisoquinoline derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014861A1 4-substituted-quinoline-8-carboxylic amide derivatives and pharmacologically acceptable addition salts thereof |
| 02/19/2004 | WO2004014859A2 Process for preparing quinolin antibiotic intermediates |
| 02/19/2004 | WO2004014847A1 Mcp-1 receptor antagonists and method of use thereof |
| 02/19/2004 | WO2004014844A2 Aryl and heteroaryl compounds and methods to modulate coagulation |
| 02/19/2004 | WO2004014835A2 Resolvins: biotemplates for therapeutic interventions |
| 02/19/2004 | WO2004014825A1 Cannabinoid receptor ligands |
| 02/19/2004 | WO2004014430A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 02/19/2004 | WO2004014428A1 Remedy for intestinal diseases and visceral pain |
| 02/19/2004 | WO2004014406A1 Use of fermented wheat germ extract as anti-inflammatory agent |
| 02/19/2004 | WO2004014397A1 Analgetic cream comprising salicylate dispersed in silicone oil and microsponges for substained delivery of counter-irritants like menthol |
| 02/19/2004 | WO2004014389A1 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014388A1 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014384A2 Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014377A1 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014375A2 Fused bicyclic metalloproteinase inhibitors |
| 02/19/2004 | WO2004014366A1 Hetero biaryl derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014365A1 Phthalimide derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014354A1 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors |
| 02/19/2004 | WO2004014352A2 Methods for treating carbonic anhydrase mediated disorders |
| 02/19/2004 | WO2004014304A2 Electrospun amorphous pharmaceutical compositions |
| 02/19/2004 | WO2004007481A3 Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders |
| 02/19/2004 | WO2004007478A3 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 02/19/2004 | WO2004000840A3 Quinuclidine derivatives and pharmaceutical compositions containing the same |
| 02/19/2004 | WO2003104473A3 Galactosyl isomalt, method for production and use thereof |
| 02/19/2004 | WO2003097852A3 Assay for identifying inhibitors of fc gamma riii signaling |
| 02/19/2004 | WO2003087318A3 Truncated 24 kda basic fibroblast growth factor |
| 02/19/2004 | WO2003082190A3 Spirocyclic amides as cannabinoid receptor modulators |
| 02/19/2004 | WO2003070188A3 Method of treating trx mediated diseases |
| 02/19/2004 | WO2003065989A3 (oxime)carbamoyl fatty acid amide hydrolase inhibitors |
| 02/19/2004 | WO2003065988A3 A combination for treating cold and cough |
| 02/19/2004 | WO2003065987A3 Granzyme b inhibitors |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003048780A3 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis |
| 02/19/2004 | WO2003045974A3 Methods and compositions for derepression of iap-inhibited caspase |
| 02/19/2004 | WO2003045411A3 Ginger extract preparation |